• Heart failure remains the most common cause of hospital admissions in the Medicare age population.
• Gaps exist in knowledge and awareness of systemic barriers to available optimizing therapies that improve survival and quality of life in heart failure patients.
• Imaging protocols afford physicians the ability to assess the heart failure patient non-invasively, and I-123 MIBG has the potential to identify heart failure patients at high risk of sudden cardiac death where implantation of a cardioverter-defibrillator may be lifesaving.
TARGET AUDIENCE
This activity is targeted at imaging professionals and is intended to provide the latest information on clinical practice and cutting-edge scientific advances in nuclear cardiology and cardiac imaging.
OBJECTIVES
After reading and reflecting upon an article in the Journal of Nuclear Cardiology, the learner should be able 1. To describe the barriers to current optimal heart failure medical treatment.
2. To understand the deleterious response of the sympathetic nervous system in heart failure and the use of I-123 MIBG imaging to assess it. 3. To describe the potential role of I-123 MIBG imaging in optimizing medical treatment for heart failure and list remaining issues for validation of this method.
ACCREDITATION AND CONTINUING EDUCATION CREDIT Physicians
The American Society of Nuclear Cardiology (ASNC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
The American Society of Nuclear Cardiology designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credits TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.
Technologists
The American Society of Nuclear Cardiology is the recognized provider of continuing education credit for technologists. ASNC's Continuing Education (ACE) credit is accepted by both the NMTCB and the ARRT. This journal-based activity has been approved for a maximum of 1 ACE credit for the technologists.
FACULTY DISCLOSURE
As an accredited provider of the ACCME, the ASNC adheres to the ACCME's 2008 Standards for Commercial Support. In compliance with these standards, it is the ASNC's policy to ensure balance, independence, objectivity, and scientific merit in all of its educational activities through the disclosure of relevant relationship with commercial companies. The financial interest or relationships requiring disclosure are outlined in the ASNC's CME Conflict of Interest Policy. All authors involved with this activity are required to disclose any relevant financial relationships.
The following author reported a financial relationship: Myron C. Gerson, MD:
Grant and research support from GE Healthcare and Lantheus Medical Imaging.
The following members of the JNC Editorial Staff reported no financial relationships: George A. Beller, MD, FASNC, and Wendy Passerell.
The following ASNC's staff and article reviewers who were involved in the planning, development, and review of this activity reported no financial relationships: Sharmila Dorbala, MD; Cathlin Bowman; Jamieson Bourque, MD; and Nancy McDonald, NCT, RT, CNMT.
OFF-LABEL USE
Articles may include discussion of drugs or devices, or uses of drugs or devices,which have not been approved by the Food and Drug Administration (FDA), or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. The ASNC is committed to the free exchange of medical education. Inclusion of any discussion in this program, including discussion on off-label uses, does not imply an endorsement by the ASNC of the uses, products, or techniques presented. 
CONTINUING EDUCATION TERM OF APPROVAL

METHOD OF PARTICIPATION
To receive a statement of credit, participants must successfully complete the quiz and evaluation questions after reading and reflecting on the article. The participant selects the single most appropriate answer for each question. A score of 80% or higher is needed to pass the quiz. If less than 80% of the questions were correct, the participant will be notified and may resubmit the quiz with modified answers up to three times. Tests will be graded by the ASNC staff members.
Estimated time for completion is 1 hour. Send your completed post-test and evaluation by mail, fax, or e-mail to:
The American Society of Nuclear Cardiology Attn: JNC Continuing Education 4340 East-West Highway, Suite 1120 Bethesda, MD 20814-4578 Fax: (301) 215-7113 E-mail: JournalCredit@asnc.org
PROCESSING FEES
The ASNC members may claim continuing education credits at no charge. Non-members will be charged $25 per activity. Please fill out the payment area included on the evaluation form.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is not supported by commercial support.
PRIVACY & CONFIDENTIALITY STATEMENT
The ASNC will record learner's personal information as provided on the CME evaluations to allow for issuance and tracking of the CME certificates. The ASNC may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
For questions regarding the CME content or obtaining the CME credit, please contact the ASNC at 301.215.7575 or info@asnc.org.
CME QUIZ & REGISTRATION FORM
In order to earn the CME credit for this journal activity, you must read the article and successfully pass the post-test. A passing grade of 80% is required to earn credit.
The CME/ACE certificates will be sent within ten (10) 
CME QUIZ
1. Which of the following statements is true regarding heart failure patients treated with beta-blockers?
a. Post-synaptic adrenergic receptors are downregulated. b. Higher doses of beta-blockers result in greater cardiovascular rehospitalization. c. There is a stepwise decrease in six-month mortality with increasing doses of carvedilol. d. Most of the benefits of beta-blockers are observed in patients with stage A heart failure.
2. Which of the following responses are observed in the cardiac sympathetic nervous system in patients with heart failure?
a. The cardiovascular response to sympathetic stimulation by angiotensin II is inhibited. b. Myocardial beta-adrenoceptor density is decreased. c. Uptake of norepinephrine into presynaptic cardiac nerve storage vesicles is increased. d. Beta-receptors are oversensitized.
3. Which of the following statements is true for cardiac neuronal imaging in heart failure? a. A heart-to-mediastinum ratio of[1.6 is associated with higher adverse cardiac events. b. The heart-to-mediastinum ratio decreases as LV function improves in response to therapy with appropriate maximal medical therapy for heart failure.
c. Impaired cardiac adrenergic innervation on I-123 MIBG is associated with higher mortality. d. I-123 imaging is of proven value to monitor response to therapy in patients treated with appropriate maximal doses of medications for heart failure. 
